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doi:10.1016/j.jtcvs.2005.08.012bjective: We sought to investigate whether intrapleural topical application of
isplatin with a surgical carrier has a prolonged local tissue level in comparison with
isplatin solution while reducing systemic toxicity.
ethods: Forty immune-competent Fischer rats were inoculated with 106 mesothe-
ioma cells. Ten days later, left pneumonectomy with tumor debulking was per-
ormed. Twenty animals underwent local application of cisplatin solution (100
g/m2), whereas the same quantity of cisplatin was topically applied as a gel with
he Vivostat (Vivolution) system in 20 other animals. In each group 5 subgroups of
animals were defined according to the harvesting time of blood and tissue samples
2, 4, 24, and 72 hours and 1 week) after local therapy. Platinum concentrations in
erum and tissue and systemic toxicity were analyzed.
esults: Platinum concentrations in tissue were significantly higher in the gel group
group 1) than in the solution group (group 2) at 1, 3, and 7 days after therapy (1510,
224, and 1069 pg/mg for group 1 vs 598, 382, and 287 pg/mg for group 2; P 
007, P  .005, and P  .0002, respectively). Laboratory findings showed renal
nsufficiency in the animals of the solution group at 1 week, with values of 98
mol/L versus 7.7 mmol/L for urea and 410 mol/L versus 43 mol/L for
reatinine (P  .02 and P  .01, respectively), which was confirmed by means of
athologic analysis.
onclusions: Intrapleural administration of cisplatin with the carrier Vivostat sig-
ificantly provides sustained higher platinum concentrations up to 1 week in tissue
n comparison with application of cisplatin solution without conferring systemic
oxicity in this model.
alignant pleural mesothelioma is increasingly observed in industrial coun-
tries. Patients with pleural mesothelioma often succumb to the compli-
cations of advanced local disease.1,2 Therefore treatment strategies often
nvolve aggressive surgical resection.3,4 However, even with a multimodal treatment
oncept, including extrapleural pneumonectomy combined with chemotherapy and
adiotherapy, local recurrence is common.1,5 Recent publications have demonstrated
n improved response rate with the cytostatic agent pemetrexed (Alimta, Lilly),
hich will be tested in a neoadjuvant setting, followed by surgical intervention.6
owever, increased local control of microscopic residual disease, which might
arkedly improve survival, requires novel therapeutic approaches.3,4,7 Malignant pleu-
al mesothelioma is an ideal model for testing new locoregional multimodality treatment
pproaches because of its aggressive local behavior.8 Because systemic chemotherapy
as had little success in mesothelioma, direct intrapleural delivery has been performed
The Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 3 697
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G
TSith the rationale of achieving high local drug concentrations
hile minimizing systemic toxicity.5,7-9 Platinum has been
ore extensively studied for intracavitary use in animals and
atients than other modes of local therapy, such as photody-
amic therapy or radiotherapy, and will probably remain one
f the keys in the chemotherapeutic approach for malignant
esothelioma.10-12 To date, platinum is still used for induction
hemotherapy in the majority of the multimodality treatment
rotocols in most experienced centers. Local application of
isplatin (Platinol, Bristol-Myers Squibb) has already been
erformed intraperitoneally in ovarian carcinoma and in-
rapleurally in malignant mesothelioma in animal models and
n patients at a dose between 80 and 150 mg/m2.5,7-9,13-16 It
as demonstrated that cisplatin given at high doses is active in
esothelioma, but the response duration was short, possibly
ecause of a lack of effective maintenance of therapy. 5,7,13
The aim of this study was to investigate whether local
opical intrapleural application of cisplatin with the aid of
urgical autologous fibrin sealant (Vivostat, Vivolution) has
prolonged local pharmacologic tissue level in comparison
ith local administration without sealant while reducing sys-
emic drug exposure in an immune-competent rat model.
ethods
nimal Model and Mesothelioma Cells
he study protocol was approved by our institution’s committee on
nvestigations involving animal subjects. Animal care was pro-
ided in accordance with the “Guide for the Care and Use of
aboratory Animals” (National Institutes of Health publication no.
6-23, revised 1985).
The animal model used in this experiment has been previously
escribed.17,18 Immune-competent Fischer rats (Harlan) were in-
culated with a syngeneic malignant mesothelioma cell line (II-45;
ells cultured from experimental asbestos-induced peritoneal me-
othelioma in rats, Research Laboratory, UT MD Anderson Cancer
enter, Smithville, Tex). Pleural mesothelioma in this model re-
embled the disease in patients histologically (malignant cells
redominantly epithelioid) and was highly reproducible (untreated
nimal dying within 4 weeks).17 Preliminarily, a proliferation
ssay using the II-45 mesothelioma cells was performed to deter-
ine the activity of different concentrations of cisplatin on a
eeding of 750 cells per well. A concentration of 1 mol/L (300
g/L) cisplatin was demonstrated to be effective at preventing and
nhibiting cell proliferation during 48 hours. In a second experi-
ent we performed a qualitative assay, demonstrating that active
isplatin could be released from the gel Vivostat-cisplatin. Necro-
is of the mesothelioma cells could be microscopically observed,
epending on the cisplatin concentration.
An effect of the cisplatin released from the gel on tumor growth
Abbreviations and Acronyms
PAS periodic acid-Schiffas also qualitatively observed in the animal model in comparison a
98 The Journal of Thoracic and Cardiovascular Surgery ● Marcith results seen in control animals in a preliminary experiment.
wo animals were still alive 14 days after administration of
isplatin with the surgical carrier after pneumonectomy and tumor
ebulking, whereas in 2 control animals without administration of
isplatin, the tumor grew again, and the animals died after 10 and
1 days, respectively.
urgical Carrier of Cisplatin
ivostat (Vivolution) is a commercialized autologous surgical
brin sealant that can be used to reduce the duration of air leak
fter lung resection or as an adjunct to hemostasis in cardiothoracic
urgery.19-21 Fibrin was obtained from 120 mL of free frozen
lasma (blood group 0) in a fully automated way, as described by
jaergard and Trumbull.21 In our study a prototype of the classical
ivostat application system was used to allow the addition of the
rug to the fibrin sealant. A system with 3 syringes was used: the
rug syringe, which contained 1 mL of cisplatin; a syringe con-
aining 1 mL of the pH 10 buffer solution; and the fibrin syringe,
hich contained 2 mL of fibrin and 1.5 mL of cisplatin. With this
omposition and after autopriming, 1.5 mL of the obtained gel was
ecessary to change the color of the pH paper from blue to light
reen, indicating that the gel was suitable for application. The 4
L of sealant, which was finally delivered to the animals with the
praypen system (Vivolution), included 0.74 mL of buffer, 1.46
L of fibrin, and 1.86 mL of cisplatin. A direct effect of the gel
btained from heterologous plasma 1 day and 1 week after appli-
ation in the rat could be excluded by comparing histologic ex-
mination of the chest wall in control rats and in animals that
eceived gel without cisplatin.
esign of the Study
orty Fischer rats with a mean weight of 283 g (range, 254-300 g)
ere included in this experiment. The animals were kept in the
odent facility of the University Hospital Zurich under veterinary
upervision before experiments. After removal from the rodent
acility, animals were kept in designated rodent-storage modules in
temperature-controlled room on a schedule of 12 hours of
ight/12 hours of darkness and were fed standard rat chow and tap
ater ad libitum. At least a 1-week acclimation period was allowed
efore each experiment.
Implantation of the malignant mesothelioma cells at day 0. Gen-
ral anesthesia was induced in an isoflurane chamber. Animals
ere intubated with a 16-gauge intravenous catheter and then
onnected to a volume-controlled ventilator (Harvard Rodent Ven-
ilator, model 683, Harvard Apparatus Co Inc) and ventilated with
xygen-halothane at a tidal volume of 10 mL/kg at 75 breaths/min
nd a positive end-expiratory pressure of 3 cm H20. The animals
ere placed in a right lateral decubitus position. After shaving and
isinfection, a 2-cm lateral thoracic incision 1 cm caudal to the left
houlder joint followed by a sharp dissection through the cutane-
us maximus muscle and identification of the ventral border of the
atissimus dorsi muscle was performed. The muscle was retracted,
evealing the intercostal muscles of the fifth intercostal space. The
hin parietal pleural membrane was visualized, and 300 L of II-45
ell suspension (1 million cells) was injected with a 28-gauge
uberculin needle without opening the pleural space. The wound
as closed in 2 layers (muscles and skin) with interrupted sutures,nd the animals were extubated.
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G
TSApplication of cisplatin at day 10. After achievement of gen-
ral anesthesia with intubation, a left lateral thoracotomy was
erformed in the fifth intercostal space (Figure E1). The left lung
as mobilized by dividing the pulmonary ligament. The hilus was
issected, and left pneumonectomy was performed after prepara-
ion and successive application of clips on the pulmonary artery,
he pulmonary vein, and the main bronchus. A tumor debulking
onsisting of the removal of most of the tumor nodules from the
hest wall and from the mediastinum was performed, followed by
mechanical pleural abrasion with an abrader (electro-surgical tip
leaner, Surgisite, Johnson & Johnson).
The 40 animals were randomly divided into 2 groups of 20
nimals each according to the means of administration of cisplatin
t a dose of 100 mg/m2 (or 3 mg/kg  1.85 mL of a solution of 10
g/20 mL of cisplatin in a 280-g rat). In 20 animals 1.85 mL of
isplatin solution plus 2.15 mL of sodium chloride were delivered
n the chest cavity, whereas in 20 animals cisplatin was mixed with
brin obtained with the Vivostat system and topically applied as a
el, as described above (Figure E2). Because of the small volume
f the chest cavity in this rat model, it was possible to completely
isualize the pleura by means of a slight traction on the chest wall
ith the rib retractor and to apply the gel homogeneously in every
art of the chest cavity. Thoracotomy was closed, as previously
escribed, and the animals were extubated. Pain therapy included
ubcutaneous injection of 1.2 mL of paracetamol (Perfalgan, 10
g/mL solution) and buprenorphine (Temgesic) at a dosage of
.1 mg/kg.
Assessment of serum and tissue samples and death. In both
roups of 20 animals, 5 subgroups of 4 animals each were defined
ccording to the time interval between application of cisplatin and
ssessment of the samples (2 hours, 4 hours, 1 day, 3 days, and 1
eek). At these different times, blood and tissue (chest wall and
idney) samples were harvested, and the animals were killed.
eath occurred after achievement of general anesthesia by using a
ombined laparotomy and sternotomy. After harvesting of the
lood samples and the kidneys, the animals were killed by means
f section of the inferior vena cava, and the left chest wall was
emoved. Tissue samples were then collected under the micro-
cope on the back table.
Blood samples. In each animal blood samples were harvested
t day 0 before the injection of cells and at death. Blood was
ithdrawn in heparin-coated syringes. Laboratory findings in-
luded determination of hemoglobin, hematocrit, white blood
ells, platelets, urea, and creatinine. A part of the sampled blood
as centrifuged (3000 rpm for 8 minutes), and the serum was
emoved, divided in 3 tubes, and frozen at 80°C for later plati-
um level determinations.
Tissue samples. At the time of death, the kidneys were har-
ested to evaluate the systemic toxicity of cisplatin according to
he means of drug delivery. The kidneys were promptly fixed in
% buffered formaldehyde. One half of the bisected kidney from
ach animal was embedded in paraffin. Two-micrometer-thick
lides were prepared from the paraffin blocks and stained as
ollows: routine hematoxylin and eosin, periodic acid–Schiff
PAS), Säurefuchsin-Orange-G-Anilinblau, and silver. The pathol-
gist was blinded to the animals and the type of treatment.
Tissue samples from the chest wall were collected on the back
able. To avoid bias caused by the repartition of cisplatin in the i
The Journal of Thoracichest, 3 samples of tissue were harvested at each time point from
predefined different locations (apical, mediastinal, and postero-
asal) to provide better information about the drug level in the
hole chest cavity. The 3 samples were homogenized and ana-
yzed for determination of the drug level and the concentration-
ime curve.
Determination of total platinum levels in serum and tissue
amples. The level of total platinum was measured by means of
nductively coupled plasma sector field mass spectrometric detec-
ion with a matrix-matched calibration procedure.22,23 The chemist
as also blinded to the animal treatment.
tatistical Analysis
tatistical analysis was carried out with SPSS software, version
1.5. Comparison of variables before implantation of the mesothe-
ioma cells and before harvesting in a group of animals at different
imes was performed by use of the paired t test. A 2-sample or
npaired t test was used to compare variables between the 2 groups
f animals at different times. To address the problem of multiple
omparison and because 5 comparisons were made in each case (at
, 4, 24, and 72 hours and 1 week), we have considered P values
maller than .05/5.01 to be statistically significant (this is like
erforming a Bonferroni correction).
esults
n all the animals, recovery was uneventful after implanta-
ion of the malignant mesothelioma cells. Four animals
ould not be extubated after left pneumonectomy and died
rom cardiorespiratory insufficiency. One animal of the
olution group was found dead in its cage 2 days after
neumonectomy and application of cisplatin. These 5 ani-
als were replaced by other rats in which recovery was
neventful.
The analysis of the platinum concentration in the pleura
howed a rapid increase of the measured values in both
roups, with a maximum of about 1500 pg/mg reached after
hours. However, the platinum concentration rapidly de-
reased in the animals of the solution group between 4 hours
nd 1 day and then more slowly until 1 week. In the animals
f the gel group, the concentration remained high between
hours and 1 day and then decreased slowly, but the
oncentration at 1 week was still 3-fold higher than the
inimal concentration of platinum required to produce ne-
rosis of the mesothelioma cells in human subjects (1
mol/L  300 g/L). The concentration of platinum in the
leura was statistically different at 1 day, 3 days, and 1
eek between the 2 groups (P  .007, P  .005, and P 
0002, respectively; 2-sample t test; Table E1 and Figure 1).
The analysis of the platinum concentration in serum also
howed a rapid initial increase in both groups of animals.
he maximum was already reached after 2 hours in the
olution group in comparison with that at 1 day in the gel
roup. There was no statistically significant difference in
erum drug levels at any time between the 2 groups accord-
ng to the mode of delivery (Table E2 and Figure 2).
and Cardiovascular Surgery ● Volume 131, Number 3 699
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G
TSAt autopsy, the pleural fluid or the gel within the chest
avity was removed and assessed for determination of plat-
num concentration. In the solution group the concentration
t 1 week could not be measured because the amount of
uid collected was not representative. The measured values
n the solution group were 245.3 pg/L at 4 hours, 132.2
g/L at 1 day, and 79.2 pg/L at 3 days, whereas the
alues in the gel group were 639.7, 401.6, 229.6, 126, and
18.6 pg/L at 2 hours, 4 hours, 1 day, 3 days, and 1 week,
espectively.
Laboratory findings showed signs of systemic toxicity at
week in the cisplatin solution group, with a significant
ecrease in thrombocyte numbers and renal insufficiency,
hereas no signs of toxicity were observed in the gel group
Table E3). These results were also confirmed when com-
aring the different laboratory parameters between the 2
igure 1. Platinum concentration in the tissue (chest wall) at
ifferent times after application in the chest cavity according to
he mode of delivery.
igure 2. Platinum concentration in the serum at different times
fter application in the chest cavity according to the mode of C
elivery.
00 The Journal of Thoracic and Cardiovascular Surgery ● Marcroups of animals before harvesting at different times (Ta-
le 1). No difference in the measured hemoglobin levels,
ematocrit levels, and leukocyte counts between the 2
roups at any time was seen.
Pathologic examination confirmed the results of the lab-
ratory tests, showing an extended acute tubular necrosis of
0% to 60% of the examined area only in the animals of the
olution group at 1 week and partially at 3 days, whereas the
xtension of the necrosis was limited (5%) in all the animals
f the gel group (Table E4). In the animals with extended
ubular necrosis, the tubules were dilated and contained
etached necrotic cells in the lumina. There was only a
esidual brush border visible in the PAS stain. Arteries and
rterioles also exhibited vacuolization of the muscle layer.
eritubular capillaries were congested (Figure E3).
No difference was seen in the histopathologic examina-
ion of the kidneys in the other animals between the 2
roups. The examination showed focal signs (10% of the
xamined surface) of osmotic nephrosis in all the animals of
oth groups at 4 hours and in 1 and 2 animals of the solution
roup and the gel group, respectively, at 1 day. The sub-
ortical tubules exhibited intracytoplasmic vacuoles, and
he brush border was intact or fragmented in the PAS stain.
he vessels, particularly the peritubular capillaries, dis-
layed hyperemia and appeared congested (Figure E4).
iscussion
he therapy of malignant pleural mesothelioma is still under
valuation. The first multimodal concept, including ex-
rapleural pneumonectomy followed by chemotherapy and
adiotherapy in selected patients with the earlier stages of
isease, showed a median survival time of 19 months.4 Our
roup initiated a new multimodality therapy concept, com-
ining neoadjuvant chemotherapy with extrapleural pneu-
onectomy and postoperative consolidating radiotherapy.1
he results of this trial were promising, and a median
urvival time of 23 months could be observed with this
ombined approach.1 However, although consolidating ra-
iotherapy was not uniformly performed in this series of
atients, local tumor relapse was common, confirming the
bservations of the largest previous reports.24-27
ABLE 1. Comparison of the laboratory tests (P values)
etween the 2 groups of animals before harvesting at
ifferent times
2 h 4 h 1 d 3 d 1 wk
emoglobin .6 .04 .4 .6 .2
ematocrit .4 .02 .06 .5 .6
eukocytes .4 .8 .05 .9 .06
hrombocytes .01 .1 .08 .4 .01
rea .5 .1 .004 .8 .02
reatinine .8 .4 .01 .9 .01
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G
TSSeveral studies evaluating local application of chemo-
herapeutic agents in the pleural cavity showed that higher
oncentrations of the drugs in the tissue could be obtained,
ut these high concentrations could not be maintained long
nough to markedly modify the course of the disease.5,7,15
n our study we decided to deliver a topical form of cisplatin
n the chest cavity and to compare the pharmacokinetic
rofile of this administration with that of the previously
ested approach with cisplatin solution. Cisplatin was mixed
ith the autologous fibrin sealant Vivostat and delivered as
gel. The advantages of the Vivostat system consisted of a
ully automated preparation process conferring a good reli-
bility of method and the possibility of delivering uniformly
nd homogeneously the gel obtained by use of an applica-
ion Spraypen in each part of the chest cavity. Additionally,
he Vivostat system overcomes the potential infective and
ntigenic risks associated with the use of most currently avail-
ble fibrin sealant and has no known adverse events.19-21
Our results could confirm the observations of the previ-
us reports, showing a rapid decrease of the platinum con-
entration in tissue only a few hours after application in the
olution group.5 A very important finding was not only that
he drug concentration in tissue was 3.7-fold higher in the
el group than in the solution group at 1 week but also that
his concentration of 1069 pg/L was still higher than the
inimal concentration of platinum active on mesothelioma
ells in human subjects.
Although no statistical difference was observed in the
easured concentrations in sera between the 2 groups,
aboratory findings demonstrated signs of systemic toxicity
t 1 week in the animals that received cisplatin solution
egarding thrombocytopenia and renal insufficiency. A pos-
ible explanation might be that the peak of serum concen-
ration in the solution group was reached earlier than at the
rst harvesting time considered in our study (2 hours).
ndeed, Rusch and colleagues5 demonstrated that systemic
bsorption was rapid after intrapleural administration of
isplatin solution, with peak serum levels being reached
ithin 1 hour of administration of intrapleural chemother-
py. The early and rapid systemic absorption of cisplatin
olution might explain the nephrotoxicity at 1 week because
delay of several days up to 1 week has already been
bserved until the apparition of the nephrotoxicity in pa-
ients who received an intravenous dose of 50 mg/m2 with-
ut prehydration.16
Several previous reports in patients showed that intra-
enous or local delivery of 100 mg/m2 cisplatin was
ssociated with an acceptable toxicity.5,8 Side effects
ere mainly gastroenterologic (nausea and vomiting,
0% to 40% of the patients) and hematologic. Neuropa-
hy and ototoxicity were seldom observed after intrapleu-
al application, and almost entirely grade 1 nephrotoxic-
ty was observed. Hanada and coworkers16 showed that h
The Journal of Thoraciclood urea levels 5 days after intravenous cisplatin ap-
lication were the best indicator of nephrotoxicity. In-
estigations in a rat model revealed that nephrotoxicity
fter injection of 1 to 5 mg/kg or infusion of 5 to 25
g/kg was ameliorated after intermittent bolus injection
nd continuous infusion (over 2 and 3 hours).13,28
In our project the delivered dose of 100 mg/m2 cis-
latin corresponded to 3 mg/kg. Therefore nephrotoxicity
f the procedure was expected to remain low. However,
istopathologic examination of the kidneys confirmed the
aboratory findings and the direct renal toxicity of cis-
latin at 1 week in the group solution, with an extended
ubular necrosis up to 60%. Hofstra and associates14
howed that the dose in patients could be escalated to 270
g/m2 in local application (solution) and that dose-lim-
ting toxicity was myelosuppression. As a consequence, it
s reasonable to think that the topical application of
igher concentrations of cisplatin with the surgical car-
ier Vivostat in human subjects might result in higher
ocal concentrations in the tissue while conferring an
cceptable low toxicity, which might be an advantage in
omparison with other modes of local therapy. Addition-
lly, the activity of the radiosensitizer cisplatin on resid-
al mesothelioma cells might be increased by the post-
perative irradiation of the operated thorax.
The transient increase of hemoglobin and hematocrit
evels at 1 day in both groups might be due to a relative
nactivity of the animals after the operation with reduced
rinking despite pain therapy.
The animal model used in this study has already been
escribed.17 Although several subcutaneous, intraperito-
eal, and intrapleural animal models for malignant mesothe-
ioma with xenografted human mesothelioma cell lines have
een reported previously, these models do not represent the
linically relevant situation of pleural-based disease in an
nimal with an intact immune system.18 The approach de-
cribed in this project has advantages over previously de-
cribed models in that it closely resembles the histologic
ppearance of pleural disease in human subjects, allows for
he study of the immune response and immunotherapeutic
odalities, enables precise quantification of tumor mass,
nd is highly reproducible, with untreated animals dying
ithin a month.17 However, a complete and precise pleu-
ectomy was technically impossible because of the absence
f an adequate layer between the pleura and the chest wall.
s a consequence and to mimic the classical pleuropneu-
onectomy in patients, we performed a mechanical pleural
brasion after tumor debulking.
We are well aware that the number of animals in each
ubgroup was relatively small. However, because of the fact
hat (1) the Bonferroni correction was applied to address the
roblem of multiple comparisons, (2) the animal model was
ighly reproducible, (3) the pathologist and the chemist were
and Cardiovascular Surgery ● Volume 131, Number 3 701
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G
TSlinded to the animal treatment, (4) the tissue samples were
arvested in a standardized manner at 3 predefined locations,
5) the concentrations of platinum in the tissue were deter-
ined twice in each animal for each harvesting time, and (6)
he histopathologic examination confirmed the results of the
aboratory findings, we think that our results are highly
ccurate.
In conclusion, our results demonstrated a significant
ocal pharmacologic advantage up to 1 week after admin-
stration of a topical form of cisplatin with the surgical
arrier Vivostat in comparison with cisplatin solution,
ithout increasing systemic toxicity in an immune-com-
etent rat model. On the basis of these results, the ad-
inistration of higher doses of cisplatin or of other
adiosensitizers with this technique might be evaluated in
everal promising multimodality therapy strategies in
xperimental settings, and phase I clinical trials might be
nitiated. We plan to analyze the activity of the cisplatin
eleased from the gel on the tumor cells by use of a
ecurrence model in the near future. We have already
stablished a reproducible recurrence model with the same
nimal in which just such a nodule of tumor can be initiated.
he effect of different doses of cisplatin on response, animal
urvival, and systemic toxicity will be assessed. In the next
xperiment the effects of a combination therapy consisting of
he topical application of cisplatin and local radiotherapy will
e evaluated.
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G
TSABLE E1. Platinum concentration in the tissue (chest wall) at different times after application in the chest cavity
ccording to the mode of delivery (mean values  standard deviation)
Solution (pg/mg) Gel (pg/mg) P value
h 749.9 11.3 782.6 23.3 .4
h 1392.1 22.9 1471.3 20 .82
d 597.7 8.2 1510.5 23.2 .007
d 382.0 12.4 1223.5 16.7 .005
wk 286.5 21.3 1069.0 18.8 .0002
ABLE E2. Platinum concentration in the serum at different times after application in the chest cavity according to the
ode of delivery (mean values  standard deviation)
Solution (pg/L) Gel (pg/L) P value
h 70.9 1.05 45.3 0.7 .11
h 60.5 0.9 46.7 0.8 .11
d 58.6 0.9 58.4 0.8 .98
d 24.0 0.9 18.7 0.4 .05
wk 17.2 0.6 14.9 0.6 .43
03.e1 The Journal of Thoracic and Cardiovascular Surgery ● March 2006
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Lardinois et al General Thoracic SurgeryABLE E3. Comparison of the laboratory tests (expressed as a mean value) before implantation of the cells and before
arvesting at different times in each group of animals (paired t test)
Solution Gel
Before implantation Harvesting P value Before implantation Harvesting P value
emoglobin (g/dL)
2 h 11.5 11.2 .7 11.8 11.5 .4
4 h 12.1 12.1 .9 10.9 13.2 .009
1 d 11.5 13.3 .03 11.5 13.7 .02
3 d 11.9 9.2 .2 10.7 9.8 .7
1 wk 12.6 11.4 .4 12.7 10.3 .006
ematocrit (%)
2 h 34.8 33.6 .3 36.6 35.9 .6
4 h 35.7 35.7 .5 32.6 40.9 .005
1 d 33.4 38.2 .01 34.4 42.5 .03
3 d 34.6 26.9 .2 34.4 29 .2
1 wk 36.4 31.3 .2 37.5 30.2 .004
eukocytes (103/L)
2 h 6.3 6.9 .5 5.8 6.4 .04
4 h 7.7 6.6 .6 5.6 6.2 .6
1 d 5.8 4.2 .1 7.7 6.3 .1
3 d 6.0 5.7 .7 5.7 5.7 .9
1 wk 4.7 10.1 .06 7.3 10.1 .007
hrombocytes (103/L)
2 h 598 575 .4 647 632 .07
4 h 578 549 .6 568 687 .07
1 d 624 502 .08 554 540 .7
3 d 524 409 .3 540 533 .9
1 wk 632 323 .005 724 621 .02
rea (mmol/L)
2 h 5.9 8.67 .06 4.8 7.9 .08
4 h 6.2 7.4 .06 5.8 10.1 .1
1 d 5.6 20.2 .02 5.1 5.4 .6
3 d 5 22.4 .02 5.2 8.5 .1
1 wk 5.7 98.2 .01 5.5 7.7 .6
reatinine (mol/L)
2 h 45.5 54.5 .6 37.3 57 .07
4 h 41.3 52.8 .08 40.8 50.3 .09
1 d 42.5 58.9 .05 38.3 41.7 .7
3 d 36 69 .1 38.3 42.8 .1
1 wk 39.3 409.8 .01 39.4 43 .8
T
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G
TSABLE E4. Histopathologic examination showing the de-
ree of tubular necrosis in the animals according to the
ode of application of cisplatin
No. of animals
Solution Gel
1% 3 (1 d) 2 (1 d)
% 0 3 (3 d)
4 (1 wk)
0% 1 (3 d) 1 (3 d)
0% 1 (3 d) 0
0%-60% 4 (1 wk) 02 (3 d)
nd Cardiovascular Surgery ● Volume 131, Number 3 703.e2
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G
TSigure E1. Intraoperative view 10 days after implantation of the
esothelioma cells showing the retracted left lung before pneu-
onectomy and the tumor nodules disseminated on the pericar-
ium, the hilus, and the chest wall.F
a
oigure E2. Intraoperative view showing the application of the gel
isplatin-fibrin sealant by use of the Spraypen with the Vivostat
ystem after left pneumonectomy.03.e3 The Journal of Thoracic and Cardiovascular Surgery ● Migure E3. Extensive acute tubular necrosis. Dilated tubules with
ecrotic detached epithelial cells, as well intraluminal calcifi-
ations, are shown. (Hematoxylin and eosin stain, original mag-
ification 400.)igure E4. Cytoplasmic vacuolization of the subcortical tubules
nd fragmentation of brush border. (Periodic acid–Schiff stain,
riginal magnification 400.)arch 2006
